Pricing Log in Create free account
Friday 6 November 2026 Export LKFT’s income statement to Excel — free account

Lakefront Biotherapeutics - Sponsored ADR

LKFT Healthcare Biotechnology

Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.

Revenue
−95.4%
EPS
+198.9%
Free cash flow
+18.2%

Quarter to June 2026, against a year earlier

33.35 0.21 −0.63%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−15.3×
Dividend yield
—
F-score
6/9
Altman Z
8.43
Beneish M
0.34
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 25.60%

Capital & Financial Ratios $m

Size
Market Cap 2,200.00
Revenue ttm 282.04
Net income ttm (652.45)
Free cash flow ttm (524.53)
Net debt Q (2,598.37)
Valuation
P/E 0.00
Forward P/E (15.30) (negative: loss-making)
Price / sales 7.87
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.58
Financial health
Current ratio Q 32.84 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (465.12)
Growth
Revenue growth Q −95.35% (below 0%: shrinking)
Operating income growth Q +46.38% (above 0%: growing)
EPS, this year −144.16% (below 0%: weak)
EPS, next year A +4.92%
Revenue, next year A −89.65% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +47.44% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −1.3×, against a ten-year median of −1.6×; over the ten years it ranged from −5.9× in 2026 to 46.5× in 2018.
P/S against its own 10 years 50.57%
10-year low 10-year high
P/B against its own 10 years 12.14%
10-year low 10-year high
EV/FCF against its own 10 years 1.02%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 3,988 3,418 3,392 2,604
Receivables 71 95 59 65
Inventory 80 55 25 10
Other 40 46 8 6
4,179 3,614 3,484 2,685
2023 2024 2025 Q'26
Payables 146 107 118 77
ST’ Debt — — — —
Other 35 — 51 2
463 363 173 82

Compound Annual Growth %

10y 5y 3y
Sales 34.03% 15.75% 33.21%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 24.62% 3.72% 11.22%

EPS $

Mar Jun Sep Dec Year
’26 0.26 — — — —
’25 (2.45) — — — 5.51
’24 1.49 — — — 1.21
’23 0.38 0.09 0.41 — 3.47
’22 (0.22) (0.31) 0.33 (3.23) (3.50)
’21 0.17 (1.18) (1.17) 0.31 (1.87)
’20 (0.86) (1.95) (1.46) (1.09) (5.46)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 8 — — — —
’25 79 — — — 1,258
’24 68 — — — 298
’23 194 163 128 — 259
’22 153 146 137 96 532
’21 150 184 76 164 574
’20 118 130 168 190 606
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (97) (39) — — —
’25 (41) (127) (245) — (291)
’24 (133) (70) (287) — (346)
’23 (101) (133) (369) — (439)
’22 (70) (147) (106) (204) (527)
’21 (146) (99) (156) (195) (596)
’20 (76) (155) (225) (32) (488)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (95) (38) — — —
’25 (46) (132) (260) — (306)
’24 (140) (141) (371) — (435)
’23 (105) (139) (379) — (458)
’22 (80) (155) (116) (214) (566)
’21 (157) (112) (174) (222) (665)
’20 (90) (168) (251) (83) (592)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 168 176 375 1,003 606 574 532 259 298 1,258 282 +25.1% 130 94 33 (70.4%)
Gross margin, % 100.00 100.00 100.00 100.00 100.00 99.66 97.61 100.00 87.35 97.33 89.75 (2.7) pt
EBT 60 (131) (34) 168 (354) (146) (227) 6 (3) 340 (96) +21.3%
EBT margin, % 35.78 (74.08) (9.19) 16.75 (58.42) (25.37) (42.58) 2.35 (1.12) 27.05 (34.08) (8.7) pt
Net income 60 (131) (35) 168 (349) (122) (230) 229 80 363 (652) +22.2%
Per share, $
Per share, $ Revenue 3.67 3.56 7.20 17.42 9.31 8.76 8.10 3.94 4.53 19.10 4.28 +20.1%
Earnings 1.29 (2.64) (0.66) 2.91 (5.36) (1.87) (3.50) 3.47 1.21 5.51 (0.29) +17.5%
Cash flow 5.80 (3.36) (3.23) 62.37 (7.50) (9.10) (8.03) (6.67) (5.26) (4.42) 0.00 n/m
Capex (0.12) (0.17) (0.31) (0.89) (1.60) (1.05) (0.58) (0.28) (1.35) (0.23) 0.00 +7.9%
Free cash flow 5.68 (3.53) (3.54) 61.49 (9.10) (10.15) (8.61) (6.95) (6.60) (4.65) 0.00 n/m
Book value 18.37 23.12 27.52 55.90 46.87 47.75 40.51 45.92 47.57 55.56 0.00 +13.1%
Shares, m 46 49 52 58 65 66 66 66 66 66 66 +4.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 80.17 0.00 0.00 0.00 0.00 11.59 0.00 0.00 9.2
P/S 47.10 50.39 12.74 11.88 10.63 6.30 5.47 4.69 3.28 4.92 7.87 15.7
P/B 3.59 3.59 3.33 3.70 2.11 1.15 1.09 0.95 0.58 0.75 0.58 2.1
EV/Sales 29.35 33.88 8.68 5.45 0.95 (3.37) (2.60) (2.44) (3.44) (3.21) (1.35) 6.3
EV/FCF 12.64 25.27 (17.65) 1.54 (0.97) 2.91 2.45 1.69 1.84 1.74 0.64 3.1
Cash, $m
Cash, $m Operating cash flow 265 (166) (168) 3,594 (488) (596) (527) (439) (346) (291) (508) n/m
Capex (5) (8) (16) (51) (104) (68) (38) (18) (89) (15) (17) +12.4%
Free cash flow 260 (175) (184) 3,542 (592) (665) (566) (458) (435) (306) (525) n/m
Balance, $m
Balance, $m Working capital 1,000 1,160 1,310 5,929 5,408 5,082 3,913 3,716 3,251 3,311 2,603 +14.2%
Net debt (1,084) (1,301) (1,524) (6,452) (5,868) (5,542) (4,298) (3,982) (3,418) (3,386) (2,598) +13.5%
Shareholders’ equity 840 1,144 1,434 3,221 3,050 3,127 2,661 3,026 3,135 3,661 3,795 +17.8%
Returns, %
Returns, % ROA 7.07 (9.86) (2.19) 3.95 (5.24) (1.93) (4.13) 4.72 1.74 8.72 0.00 +1.7 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 75.88 0.00 +75.9 pt
ROE 9.60 (13.19) (2.68) 7.21 (11.13) (3.95) (7.94) 8.06 2.60 10.68 0.00 +1.1 pt
People
People Employees 508 600 725 1,003 1,304 1,309 1,338 1,123 704 452 — (1.3%)
Revenue/emp, $m 0.33 0.29 0.52 1.00 0.46 0.44 0.40 0.23 0.42 2.78 — +26.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026

Lakefront Biotherapeutics - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VCEL Vericel Corporation $2.7B 77.8× 72.9× +26.47% (above 0%: growing) +180.00% (above 0%: growing) −19.39% (below 0%: shrinking) 73.34% 14.27% Compare
PVLA Palvella Therapeutics, Inc. $2.3B — (loss-making) — (loss-making) −99.09% (below 0%: shrinking) n/m −136.38% (below 0%: shrinking) 100.00% 0.00% Compare
SEPN Septerna, Inc. $2.2B — (loss-making) — (loss-making) +22,375.63% (above 0%: growing) n/m −9.01% (below 0%: shrinking) 100.00% (62.95%) Compare
LKFT Lakefront Biotherapeutics - Sponsored ADR $2.2B — (loss-making) — (loss-making) −95.35% (below 0%: shrinking) +198.85% (above 0%: growing) +18.22% (above 0%: growing) 25.95% (982.91%)
AUPH Aurinia Pharmaceuticals Inc $2.2B 6.8× 17.6× +13.93% (above 0%: growing) 0.00% +4.41% (above 0%: growing) 90.08% 40.74% Compare
VERA Vera Therapeutics, Inc. $2.2B — (loss-making) — — n/m −82.47% (below 0%: shrinking) 0.00% 0.00% Compare
IMNM Immunome, Inc. $2.1B — (loss-making) — (loss-making) +69.84% (above 0%: growing) n/m −26.96% (below 0%: shrinking) 100.00% 0.00% Compare
BHVN Biohaven Ltd. $2.1B — (loss-making) — (loss-making) +131.43% (above 0%: growing) n/m +26.55% (above 0%: growing) 0.00% 0.00% Compare
ZYME Zymeworks Inc. $2.0B — (loss-making) 26.0× −90.58% (below 0%: shrinking) n/m −385.53% (below 0%: shrinking) (497.71%) (918.95%) Compare
Median of peers $2.2B — 26.0× +26.47% — −23.17% 81.71% 0.00%

All 621 Biotechnology stocks →

Lakefront Biotherapeutics - Sponsored ADR (LKFT) Latest News

21 Oct

Impact 3 · · Zacks
Impact 3 · · Simply Wall St.

20 Oct

Impact 3 · · GlobeNewswire

14 Oct

Impact 3 · · GlobeNewswire

6 Oct

Impact 3 · · GlobeNewswire

29 Sep

Impact 3 · · GlobeNewswire

23 Sep

Impact 3 · · MT Newswires

21 Sep

Impact 4 · · MarketBeat

15 Sep

Impact 3 ·

24 Aug

Impact 4 ·

10 Aug

Impact 3 ·

28 Jul

Impact 3 ·

9 Jun

Impact 3 · · GlobeNewswire

7 Jun

Impact 4 · · Insider Monkey

4 Jun

Impact 4 ·
Impact 4 ·

7 May

Impact 3 · · MarketBeat

6 May

Impact 3 · · GlobeNewswire

4 Apr

Impact 4 · · Insider Monkey

31 Mar

Impact 4 · · MarketBeat
Impact 4 · · Simply Wall St.
Impact 4 · · GlobeNewswire

24 Mar

Impact 4 · · Barrons.com

23 Mar

Impact 4 · · GlobeNewswire

6 Mar

Impact 4 · · GlobeNewswire

24 Feb

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat

23 Feb

Impact 4 · · GlobeNewswire

4 Feb

Impact 3 · · PR Newswire

10 Jan

Impact 3 · · Simply Wall St.

LKFT metrics, ten years each

stockrow.com/LKFT · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com